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Elevated levels of myeloid-der ived suppressor cel ls (MDSCs), including
polymorphonuclear MDSCs (PMN-MDSCs) and immature MDSCs (I-MDSCs), are
usually associated with disease progression in cancer patients, including colorectal
cancer (CRC). However, biological mechanisms and molecular pathways regulated by
MDSC subpopulations in the CRC tumor microenvironment (TME) have not been fully
investigated. In this study, we performed transcriptomic analysis of tumor-infiltrating I-
MDSCs and PMN-MDSCs isolated from tumor tissues of six CRC patients, compared to
antigen-presenting cells (APCs). We also compared the transcriptomic profiles of tumor-
infiltrating PMN-MDSCs to I-MDSCs. Our results showed different molecular pathways
regulated by each MDSC subset, potentially reflecting their phenotypical/molecular/
functional characteristics in the CRC TME. Moreover, we identified gene signatures in
PMN-MDSC and I-MDSC of poor overall survival (OS) and disease-free survival (DFS)
using the Cancer Genome Atlas (TCGA) dataset from patients with colon adenocarcinoma
(COAD). However, functional studies are required to validate these findings.
Keywords: myeloid-derived suppressor cells, colorectal cancer, transcriptomic profiling, metabolism, signaling
pathways, immune responsesINTRODUCTION
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells,
halted at varying stages of maturation/differentiation and exert immunosuppressive activity on
other immune cells (1, 2). MDSCs have been divided into different subpopulations based on
their phenotypical and functional characteristics; early-stage or immature MDSCs (e-MDSC/
I-MDSC) identified as CD33+HLA-DR-/lowCD14-CD15-, monocytic MDSCs (M-MDSCs) identifiedAbbreviations: APCs, Antigen presenting cells; CRC, Colorectal cancer; DC, Dendritic Cells; I-MDSCs, Immature-myeloid
derived suppressor cells; IL-3, Interleukin-3; IL-6, Interleukin-6; MDSCs, Myeloid-derived suppressor cells; MAPK, Mitogen-
activated protein kinase; NFAT, Nuclear factor of activated T-cells; PMN-MDSCs, polymorphonuclear/granulocytic-myeloid
derived suppressor cells; PPI network, Protein-protein interaction network; TME, Tumor microenvironment.
November 2020 | Volume 10 | Article 6049061
Saleh et al. Tumor-Infiltrating MDSCs in CRCas CD33+HLA-DR-/lowCD14+CD15-, and polymorphonuclear
MDSCs (PMN-MDSCs) identified as CD33+HLA-DR-/lowCD14-
CD15+ (1, 3, 4). Myelopoiesis is disrupted in inflammation-
related cancers (5), such as colorectal cancer (CRC), leading to
increased number of MDSCs in the circulation and tumor tissues
(1, 2).
The contribution of MDSCs to cancer pathogenesis and
progression is well-established (3, 6). Increased level of MDSCs
has been associated with poor prognosis and short survival
periods in CRC patients (7–9). MDSCs within the tumor
microenvironment (TME) exert their suppressive activity on T
cells to inhibit their anti-tumor activities (6, 10). MDSCs mediate
immunosuppression by expressing co-inhibitory ligands, such as
PD-L1, which induces T cell dysfunction upon the interaction
with its receptor PD-1, and by expressing suppressive molecules,
such as arginase-1 (ARG1), inducible nitric oxide synthase
(iNOS), interleukin-10 (IL-10), and transforming growth factor-
b (TGF-b) (11, 12). Furthermore, MDSCs promote tumorigenesis
via other means, such as the induction of angiogenesis and tumor
growth/metastasis, and activation of cancer-associated fibroblasts
(CAFs) (12, 13). Up to date, the biological mechanisms and
signaling pathways regulated by MDSC subpopulations have not
been fully explored. Thus, further insights into these mechanisms
and pathways could result in the identification of potential
therapeutic targets for cancer.
Previously, we reported increased number of PMN-MDSCs
and I-MDSCs in CRC tumor tissues, compared to paired-normal
tissues (14), implicating the importance of MDSC role in CRC
tumorigenesis and immunosuppression (7). Additionally, we
reported the transcriptomic profiles of CRC tumor-infiltrating
I-MDSCs and PMN-MDSCs from tumor tissues of only two
patients, compared to antigen-presenting cells (APCs) (14). In
this study, we extended our investigation and included more
CRC patients.
We found that immune response-mediated pathways
associated with dendritic cell (DC) maturation (15), triggering
receptor expressed on myeloid cells 1 (TREM1) signaling (16),
nuclear factor of activated T cells (NFAT)-mediated regulation
of immune response (17), and Fcg receptor-mediated
phagocytosis (18) were commonly downregulated in PMN-
MDSCs and I-MDSCs, compared to APCs. We also compared
the transcriptomic profiles of PMN-MDSCs vs. I-MDSCs and
found that pathways supporting tumor growth and survival,
related to metabolism, lipid biosynthesis, stress response,
increased production of glucose and interaction between DCs
and natural killer (NK) cells were different in tumor-infiltrating
PMN-MDSCs and I-MDSCs. Therefore, these results may
reflect the molecular profile and functional characteristics of
each MDSC subset in the CRC TME. We also validated RNA-
Seq data by confirming the mRNA expression of selected
genes in the different myeloid subpopulations using qRT-
PCR. We also utilized the Cancer Genome Atlas (TCGA)
from patients with colon adenocarcinoma (COAD) to analyze
our RNA-Seq data and identify gene signatures for PMN-
MDSC and I-MDSC to predict overall survival (OS) and
disease-free survival (DFS).Frontiers in Oncology | www.frontiersin.org 2MATERIALS AND METHODS
Sample Collection and Storage
Tumor tissues (TT) were obtained from six CRC patients (#05,
07, 08, 09, 44, and 53) who underwent surgery at Hamad Medical
Corporation, Doha, Qatar. Demographical details and
clinicopathological features of study population are shown in
Table 1. These patients were treatment-naïve prior to surgery
and provided written informed consent prior to sample
collection. This study was performed under ethical approvals
from Hamad Medical Corporation, Doha, Qatar (protocol no.
MRC-02-18-012) and Qatar Biomedical Research Institute,
Doha, Qatar (protocol no. 2018-018). Tissue specimens were
frozen in 1 ml of freezing medium (10% dimethyl sulphoxide
(DMSO; Sigma-Aldrich, Missouri, USA), 50% fetal calf serum
(FCS; HyClone, GE Healthcare Life Sciences, Utah, USA), and
40% RPMI-1640 medium (Life Technologies, New York, USA)),
then stored in liquid nitrogen to be used in batches for
subsequent analyses. Tissue specimens were thawed and
processed, as previously described, followed by cell staining/
sorting (14, 19–21).
Theflowchart for the experimental design and tissue processing
is shown in Figure 1. All experiments were performed in
accordance with relevant guidelines and regulations.
Dissociation of Tissue and Cell Sorting
Tissue specimens were thawed and processed, as previously
described (14) and as shown in Figure 1. Single cell
suspensions were isolated from six frozen CRC tissues (Patient
#05, 07, 08, 09, 44, and 53) using gentleMACS Dissociator
(Miltenyi Biotec), washed and stained with 7-AAD viability
dye (eBioscience, San Diego, USA) to gate live cells, and for
different cell surface markers; CD33-Fluorescein isothiocyanate
(clone HIM3-4; BD Biosciences, Oxford, UK), CD14-
phycoerythrin-Cy7 (clone M5E2; BD Biosciences), CD15-
allophycocyanin (clone HI98; BioLegend, San Diego, USA),
HLA DR-phycoerythrin (clone G46-6; BD Biosciences), to sort






II 2 (CRC #07 & 44)
III 2 (CRC#05 & 08)
IV 2 (CRC #09 & 53)
Anatomical location
Cecum 2 (CRC #07 & 44)
Transverse colon 2 (CRC #08 & 53)
Sigmoid 1 (CRC #09)
Rectum 1 (CRC #05)
Histological grade
G2—Moderately differentiated All samplesNovember 2020 | Volume 1CRC, colorectal cancer.
†Data shown represent median (range).0 | Article 604906
Saleh et al. Tumor-Infiltrating MDSCs in CRC(Figure 1). For cell sorting, BD FACSAria III SORP cell sorter
was utilized, with BD FACSDiva software (BD Biosciences). We
used stringent gating strategy and applicable measures were
taken to ensure minimal sorter-induced cell stress (SICS). High
purities of the sorted myeloid cell subpopulations were always
checked and confirmed. FlowJo V10 software (FlowJo, Ashland,
USA) was used for data analyses.
RNA Extraction and Reverse Transcription
Total RNA was extracted from sorted pure myeloid subsets,
CD33+HLA-DR+CD14+CD15- (APCs), CD33+HLA-DR-CD14-
CD15+ (PMN-MDSCs), and CD33+HLA-DR-CD14-CD15- (I-
MDSCs) using RNAqueous-Micro Total RNA isolation Kit
(Thermo Fisher Scientific). Purified RNA was then amplified
using 5X MessageAmp II aRNA Amplification Kit (Thermo
Fisher Scientific). Before and after amplification, RNA
concentrations were determined by Qubit RNA HS and Broad
Range Assay Kits, (Invitrogen). For reverse transcription,
QuantiTect Reverse Transcription Kit (Qiagen, Hilden,
Germany) was used to convert 1 µg of RNA into cDNA.
Library Preparation
cDNA libraries were generated using Exome TruSeq Stranded
mRNA Library Prep Kit (illumina, San Diego, USA) following
the manufacturer’s protocol, as previously described (22).
Libraries that passed quality control were subjected toFrontiers in Oncology | www.frontiersin.org 3clustering using TruSeq PE Cluster Kit v3-cBot-HS
(illumina). Sequencing of clustered samples was performed
on an illumina HiSeq 4000 instrument using HiSeq 3000/
4000 SBS kit (illumina).RNA Sequencing Data and Functional
Annotation Analyses
As previously described, 150 bp depth paired-ends reads were
trimmed and aligned to the hg19 human reference genome in CLC
Genomics Workbench-12 (Qiagen) using default settings (14, 22).
The abundance of gene expression is determined by the score of
TPM (Transcripts Per Million), mapped reads in CLC Genomics
Workbench 12. Hierarchical clustering, principal component
analysis (PCA) and differential gene expression analyses were
performed, as previously described (23), using 2.0-fold change
and P value <0.05 cutoffs. Ingenuity Pathways Analysis (IPA)
software (Ingenuity Systems; www.ingenuity.com) was utilized to
perform functional and pathway analyses on differentially
expressed genes, as described previously (14, 22). Raw data
comparing myeloid subsets are shown in Supplementary Table
1. The flow chart for the bioinformatic tools used for RNA-Seq
analysis is shown in Figure 1. Protein-protein interaction (PPI)
networks among the significantly up/downregulated genes were
determined by web-based online tool, STRING V11.0 (http://
string-db.org).FIGURE 1 | Pipeline for the experimental design and RNA-Seq analysis. Flow chart showing the study design, gating strategy used for cell sorting and bioinformatic
tools used for RNA-Seq data analysis.November 2020 | Volume 10 | Article 604906
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Transcription PCR
QuantStudio 6/7 Flex Real-time PCR system (Applied
Biosystems, California, USA) was used to perform qRT-PCR
for genes including CSF2, IL1B, PRF1, GZMA, IFNG, IL2RA,
CD40, and b-actin with PowerUp SYBR Green Master Mix
(Applied Biosystems). The relative mRNA expression was
determined by the normalization to b-actin, and represented as
the mean (log10) ± standard error of the mean (SEM).
Supplementary Table 2 lists the sequences for the primers used.
The Cancer Genome Atlas Analysis for
RNA Sequencing Data
From our RNA-Seq data, the top 200 upregulated genes and 200
downregulated genes in PMN-MDSC vs. APC and I-MDSC vs.
APC were selected for overall survival (OS) and disease-free
survival (DFS) analyses using the GEPIA2 database, on a cohort
of 269 patients with colon adenocarcinoma (COAD) from the
Cancer Genome Atlas (TCGA) dataset. The 200 genes were
subjected to univariate survival analysis and genes exhibiting
poor survival and significant Log-rank test P value (≤0.05) were
identified. The refined gene list was then subjected to forward
combined gene survival analysis and genes that improved the
performance (lower Log-rank test P value) were retained, while
those that did not were dropped from the signature. Analysis
were conducted employing the GEPIA2 algorithm, as detailed
previously (24). Patients were divided into high and low groups
based on median gene expression; top 50% was designated as
high and bottom 50% was designated as low, and the Log-rank
test was used for curve comparison. The survival signature score
is calculated by mean value of log2(TPM + 1) of each gene.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism 8
software (GraphPad Software, California, USA). For samples that
passed the Shapiro-Wilk normality test, paired t-tests were
performed, while those which did not pass the normality test were
subjected to Wilcoxon signed-rank tests. Statistically significant P
values are represented as follows; ***P < 0.001, **P < 0.01, *P < 0.05.RESULTS
Hierarchical Clustering and Comparisons
of Differentially Expressed Genes in
Colorectal Tumor-Infiltrating PMN-MDSC,
I-MDSC-MDSC, and APCs
We have previously reported that levels of PMN-MDSCs, I-
MDSCs, and APCs in TT are higher than those in NT from the
same CRC patients (7, 14). In this study, we performed RNA-Seq
to characterize the differential gene expression in these myeloid
subsets. The gating strategy for sorting myeloid subsets was
previously described (14) and as shown in Figure 1.
CD33+HLA-DR-/lowCD14-CD15+ were identified as PMN-
MDSCs, CD33+HLA-DR-/lowCD14-CD15- were identified as I-
MDSCs, and CD33+HLA-DR+CD14+ were identified as APCs.Frontiers in Oncology | www.frontiersin.org 4The hierarchal clustering shows a distinct cluster of genes
which are differentially regulated in the tumor-infiltrating
PMN-MDSC and I-MDSC, compared with APCs, from six CRC
patients (Figure 2A). We found that a total of 3,133 upregulated
genes in PMN-MDSC and 824 downregulated genes, compared to
APCs. A total of 1,206 genes were upregulated in I-MDSC and 940
genes were downregulated in I-MDSC, compared to APCs.
Additionally, we found that 788 genes were upregulated and 253
genes were downregulated in PMN-MDSC, compared to I-MDSC.
Principal component analysis (PCA) showed that datasets for the
myeloid populations (PMN/I-MDSC) were clustered distinctly
from the control APCs suggesting the similarity of gene
expression patterns in MDSC subsets, compared to APCs
(Figure 2B). MDSCs clustered distinctly from APCs within the
first two principal components, accounting for approximately
48.6% of the observed variation (Figure 2B). Volcano plot
shows the genes that were upregulated (shown in red),
downregulated (shown in green), or remained unchanged
(shown in grey) when comparing PMN-MDSC vs. APC (Figure
2C), I-MDSC vs. APC (Figure 2D) and PMN-MDSC vs. I-MDSC
(Figure 2E). Only genes that were significantly up/down-
regulated, with a fold change > 2 and P value < 0.05 cutoffs
were selected for subsequent analyses.
Functional Annotation Analyses of
Colorectal Tumor-Infiltrating PMN-MDSCs
and I-MDSC-MDSCs
APCs are responsible for antigen processing and presentation to
activate adaptive immune responses, while MDSCs are known to
suppress immune responses (25). In agreement with this, our
RNA-Seq data confirmed these functional characteristics of
myeloid subpopulations. We analyzed the differentially
expressed genes in colorectal tumor-infiltrating PMN-MDSCs
and I-MDSCs, compared to APCs (Figures 3A, B). Functional
annotation analyses for top significantly affected transcripts, with a
fold change > 2 and P value < 0.05 cutoffs, showed that genes
related to immune system processes, positive regulation of
immune response, and defense responses were downregulated in
PMN-MDSCs, compared to APCs (Figure 3A). Additionally,
genes involved in DC maturation, Fcg receptor-mediated
phagocytosis and NFAT-mediated regulation of immune
response were significantly downregulated in PMN-MDSCs
(Figure 2A). On the other hand, genes related to ketogenesis and
potentially associated with resistance to cancer immunotherapy
(anti-PD-1/PD-L1) were upregulated in PMN-MDSCs (Figure
3A). We also found that genes involved in the positive regulation
of immune response, immune system processes and defense
responses were downregulated in I-MDSCs (Figure 2B).
Furthermore, genes related to IL-8, IL-6, CXCR4 and IL-3
signaling pathways, Toll-like receptor signaling pathways and DC
maturation were significantly downregulated in I-MDSCs (Figure
3B). These data showed the functional characteristics of PMN-
MDSCs and I-MDSCs as compared to APCs, and the different
pathways associatedwith immune response regulation, whichwere
downregulated in tumor-infiltrating PMN-MDSCs and I-MDSCs
from CRC patients.November 2020 | Volume 10 | Article 604906
Saleh et al. Tumor-Infiltrating MDSCs in CRCWe found that genes related to oxidative phosphorylation,
histamine degradation and NF‐E2‐related factor 2 (NRF2)-
mediated oxidative stress response were upregulated in PMN-
MDSCs, compared to I-MDSCs (Figure 3C). However, genes
associated with the crosstalk between DCs and natural killer
(NK) cells were significantly downregulated in PMN-MDSCs,
compared to I-MDSCs (Figure 3C). These findings suggest that
pathways related to metabolism, stress response and interaction
between DCs and NK cells vary in colorectal tumor-infiltrating I-
MDSCs vs. PMN-MDSCs.
Next, we performed protein-protein interaction (PPI) and
enrichment network analysis, using STRING web-based tool, to
show the interactions of proteins within the significantly affected
pathways within myeloid subsets. For this analysis, we selected
deregulated genes from PMN-MDSC vs. APC (Supplementary
Figure 1), I-MDSC vs. APC (Supplementary Figure 2) and
PMN-MDSC vs. I-MDSC (Supplementary Figure 3). For PMN-
MDSC vs. APC, STRING database identified 72 nodes and 120
edges with PPI enrichment P value <1.0E-16, average clustering
coefficient of 0.404 and average node degree of 3.33
(Supplementary Figure 1). Additionally, for I-MDSC vs. APCFrontiers in Oncology | www.frontiersin.org 5STRING database identified 76 nodes and 191 edges with PPI
enrichment P value <1.0E-16, average clustering coefficient of
0.493 and average node degree of 5.03 (Supplementary Figure
2). Finally, for PMN-MDSC vs. I-MDSC, STRING database
identified 37 nodes and 74 edges with PPI enrichment P value
<1.0E-16, average clustering coefficient of 0.706 and average
node degree of 4 (Supplementary Figure 3). In concordance
with the IPA pathway analyses, we identified significant network
of immune regulation in both PMN-MDCS/I-MDSC vs. APC
and oxidative phosphorylation in PMN-MDSC vs. I-MDSC
(Supplementary Figures 1-3). These data further confirm the
significance of identified networks form IPA pathway analyses.
Up/Downregulated Canonical Pathways in
Colorectal Tumor-Infiltrating PMN-MDSCs
Next, differentially expressed genes in colorectal tumor-
infiltrating myeloid subpopulations were subjected to Ingenuity
Pathway Analysis (IPA). Based on our analysis, we identified
canonical and signaling pathways that were differentially
upregulated or downregulated in tumor-infiltrating PMN-
MDSCs and I-MDSCs (Figure 4). We found that TREM1A B
D E
C
FIGURE 2 | Hierarchical clustering and comparison of myeloid cell subpopulations (PMN-MDSCs, I-MDSCs and APCs) in tumor tissue of CRC patients. Cells
isolated from tumor tissues of six CRC patients were stained for myeloid cell markers and sorted for RNA extraction. Hierarchical clustering of APCs, I-MDSCs and
PMN-MDSCs from six tumor tissues (CRC patients #05, 07, 08, 09, 44 and 53) based on differentially-expressed RNA transcripts. Each column represents a sample
and each row represents a transcript. Expression level of each gene in a single sample is depicted according to color scale (A). Principle component analysis (PCA)
based on the differentially expressed genes in each myeloid subpopulation (B). Volcano plots show genes that were upregulated (shown in red), downregulated
(shown in green) or remained unchanged (shown in grey) when comparing PMN-MDSC vs. APC (C), I-MDSC vs. APC (D) and PMN-MDSC vs. I-MDSC (E).November 2020 | Volume 10 | Article 604906
Saleh et al. Tumor-Infiltrating MDSCs in CRCsignaling, NFAT regulation of the immune response, Fcg
receptor-mediated phagocytosis in macrophages and
monocytes and DC maturation were downregulated in PMN-
MDSCs, compared to APCs (-5.0 < Z score > -3.0, Figure 4A).
On the other hand, pathways related to arginine biosynthesis,
cancer immunotherapy and cell cycle were upregulated in PMN-
MDSCs (2.0 < Z score > 3.0, Figure 4A).
Up/Downregulated Canonical Pathways in
Colorectal Tumor-Infiltrating I-MDSCs
We found that pathways related to TREM1 signaling, leukocyte
extravasation, DC maturation, NFAT regulation of the immune
response, Fcg receptor-mediated phagocytosis in macrophages
and monocytes, IL-8 signaling, IL-6 signaling, Toll-like receptor
signaling, LPS-mediated MAPK signaling, CXCR4 and IL-3
signaling were all downregulated in I-MDSCs, compared to
APCs (-4.0 < Z score > -2.0, Figure 4B). On the other hand,
PPAR pathway was upregulated in I-MDSCs (Figure 4B).
Up/Downregulated Canonical Pathways in
Colorectal Tumor-Infiltrating PMN-MDSCs
Next, we compared pathways that were differentially upregulated
or downregulated in PMN-MDSCs, compared to I-MDSCs. We
found that pathways related to the crosstalk between DCs and
NK cells were downregulated, while pathways related to
oxidative phosphorylation, ketogenesis, glycolysis, glucogenesis,
cholesterol biosynthesis and NRF2-mediated oxidative stressFrontiers in Oncology | www.frontiersin.org 6response were all upregulated in PMN-MDSC, compared with
I-MDSCs (-3.0 < Z score > 6.0, Figure 4C). These findings
suggest that pathways related to metabolism, stress response,
histamine degradation and interaction between DCs and NK
cells are different in tumor-infiltrating I-MDSCs and PMN-
MDSCs. Thus, they provide novel insights into the functional
pathways regulated by each MDSC subset in the colorectal TME.
qRT-PCR Validation of Selected Gene
Expression in Colorectal Tumor-Infiltrating
PMN-MDSC and I-MDSC
We validated the expression of selected genes from RNA-Seq
data in tumor-infiltrating PMN-MDSCs, I-MDSCs and APCs
(the latter used as a control) by qRT-PCR. The selected genes
were amongst the top significantly affected transcripts with a fold
of change >2 and P value cutoff <0.05. We validated that IL1B,
IL2RA, and CD40 genes were downregulated in PMN-MDSCs
(Figure 5A); these genes are important for APC and T cell
activation (26–28). We validated that CSF2 and GZMB gene
expressions were upregulated in PMN-MDSC (Figure 5A); these
genes encode GM-CSF and granzyme B, respectively.
Upregulated expression of GM-CSF and granzyme B in PMN-
MDSC could be associated with their capability of recruiting
neutrophils in the TME, which potentially increases tumor-
associated neutrophils, and releasing cytolytic molecules to kill
immune cells that positively regulate anti-tumor immunity (29).
We also validated the downregulation of IL1B and theA B C
FIGURE 3 | Differential gene expression of PMN-MDSCs, I-MDSCs and APCs in CRC tumor microenvironment. Functional categorization of top significantly
upregulated and downregulated transcripts (with a fold change > 2, P value cutoff < 0.05) from CLC analysis were analyzed through IPA. Heat maps show the TPM
representing fold change relative to the mean expression in PMN-MDSC (denoted as PMN) vs. APC (A), I-MDSC (denoted as I) vs. APC (B) and PMN-MDSC vs. I-
MDSC (C).November 2020 | Volume 10 | Article 604906
Saleh et al. Tumor-Infiltrating MDSCs in CRCupregulation of IFNG, GZMB, CSF2, and PRF1 genes in I-
MDSCs, compared to APCs (Figure 5B). Although the
upregulated genes, IFNG, GZMB and PRF1 (PRF1 encodes
perforin 1), have been implicated in CD8+ T cell activation
and function (30), they could be also associated with the
promotion of I-MDSC suppressive function to enhance PD-L1
expression and kill reactive CD8+ T cells and favor tumor growth
(31–33). Finally, we validated the upregulation of IL1B and the
downregulation of IFNG and IL2RA genes in PMN-MDSCs,
compared to I-MDSCs (Figure 5C). This latter finding suggests
that PMN-MDSCs and I-MDSCs can mediate different pathways
and induce different effects on the immune response and
tumor microenvironment.
TCGA Analysis Revealed Gene Signatures
in Tumor-Infiltrating PMN-MDSC and I-
MDSC Associated With Poor Prognosis in
Patients With Colorectal Adenocarcinoma
Survival analysis of top downregulated genes in PMN-MDSC vs.
APC identified NPL, CATSPER1, PRAM1, SLC11A1, APOE,
and TREM2 as poor OS prognostic markers in COAD using
univariate analysis. High gene signature of TREM2, CATSPER1,
NPL, and PRAM1 had the highest prognostic value (Log-rank
P = 0.0076, HR(high)=1.9) (Figure 6A). On the other hand, high
signature of RBP7, IL3RA, and TBXAS1 correlated with worse
DFS in COAD. TBXAS1 alone exhibited the highest prognostic
value [Log-rank P = 0.018, HR(high)=1.8] for DFS (Figure 6B).
Additionally, I-MDSC vs. APC-derived gene signature was
subjected to OS and DFS analysis. Using univariate analysis,
we found that GPNMB, INHBA, CATSPER1, HAMP, HTRA4,
NPL, PRAM1, TNNT1, SLC11A1, and TREM2 predicted worse
OS, while INHBA, TNNT1, and IL3RA predicted worse DFS.
Combination of TNNT1, NPL, and CATSPER1 had the
strongest prognostic power for OS [Log-rank P = 7.7e−05, HR
(high)=2.7], while combination of (TNNT1, IL3RA, and
INHBA) was associated with worst DFS [Log-rank P =
0.00038, HR(high)=2.4] (Figures 6C, D). It is worth noting
that top upregulated genes in PMN-MDSC or I-MDSC vs.
APC had little impact on prognosis and survival rates, hence,
they were not included in these analyses.DISCUSSION
Increased MDSC numbers in CRC tumor tissues, compared to
paired-normal tissues have been previously reported, implicating
the importance of MDSC function in tumorigenesis and
immunosuppression (14). We have previously reported the
transcriptomic profiles of CRC tumor-infiltrating I-MDSCs
and PMN-MDSCs, compared with APCs (14). We found that
pathways related to JNK and Wnt signaling, and SNARE
complex activation were upregulated in I-MDSCs. Meanwhile,
pathways related to CRC progression, cell migration, and MDSC
recruitment were upregulated in PMN-MDSCs (14). These
findings were obtained from RNA-Seq data analyses in two
CRC patients (14). In this study, we included more patientFrontiers in Oncology | www.frontiersin.org 7samples in order to identify additional variations and
emergence of different signaling pathways. Moreover, it is
noteworthy that sorting few cells of different myeloid subsets;
therefore, it was challenging to perform RNA extraction from
few cells and additional amplification steps were required. Few
studies have reported that cryopreservation/thawing procedure
can reduce the proportion of MDSC subsets in the circulation
(peripheral blood mononuclear cells; PBMC) and the expression
of arginase-1 (34, 35). However, the use of cryopreserved PBMC
samples is acceptable as no significant changes were seen in the
number of the most suppressive MDSC subset, PMN-MDSC, in
fresh versus cryopreserved PBMC (36). We have also shown that
expression of arginase-1 mRNA in CD33+HLA-DR- myeloid
cells, presumably suppressive subsets of myeloid cells, in
cryopreserved PBMC is higher than that of CD33+HLA-DR+
APCs (37). Additionally, we have sorted different MDSC subsets
from tumor tissue, which could be less susceptible to be affected
by freeze-thaw procedure, unlike PBMC.
Hierarchical cluster analysis and PCA showed that variations
within myeloid subsets (I-MDSCs and PMN-MDSCs) are
much less than those compared between myeloid subsets and
APCs. These data confirm the differences in the functionalA
B
C
FIGURE 4 | Canonical and signaling pathway analyses of myeloid
subpopulations in the CRC tumor microenvironment. Functional
categorization of top significantly upregulated and downregulated transcripts
(with a fold change > 2, P value cutoff < 0.05) from CLC analysis were
analyzed through IPA. Top significantly affected (1.5 > Z score < -2.0)
canonical pathways were analyzed by IPA. The horizontal bars denote the
different pathways based on the Z-scores; PMN-MDSC vs. APC (A), I-MDSC
vs. APC (B) and PMN-MDSC vs. I-MDSC (C).November 2020 | Volume 10 | Article 604906
Saleh et al. Tumor-Infiltrating MDSCs in CRCcharacteristics of MDSCs versus APCs. In support of this, we
found that genes associated with DC maturation, positive
regulation of immune response, immune system processes and
defense response were downregulated in PMN-MDSCs,
compared with APCs. DCs, which also function as APCs, play
an important role in the activation of anti-tumor immunity (15).
DC maturation is very important for the activation of adaptive
immunity and T cell responses (15). One of the mechanisms by
which cancer cells evade anti-tumor immunity is by
compromising APC function and DC maturation (38).
Genetic, epigenetic and cell-mediated mechanisms can
contribute to APC dysfunction and impaired DC maturation
(39). Some of these cell-mediated mechanisms are driven by the
action of MDSCs. Tan et al. reported that PMN-MDSCs,
induced by modified vaccinia TianTan in mesothelioma mouse
model, suppress DC function by releasing IL-10, resulting in the
impaired induction of anti-tumor cytotoxic T cell response (40).
In another study, PMN-MDSCs were shown to suppress DC
maturation and T cell proliferation in autoimmune arthritis
mouse model (41). In addition to DC maturation, we found
that other immune response-related pathways, such as TREM1Frontiers in Oncology | www.frontiersin.org 8signaling (16), NFAT-mediated regulation of immune response
(17) and Fcg receptor-mediated phagocytosis (18), were
downregulated in PMN-MDSCs, compared to APCs. On the
other hand, PMN-MDSCs showed an upregulation of pathways
related to arginine biosynthesis, which potentially lead to
increased production of arginine and its consumption by
tumor cells to maintain their survival and growth (42, 43), and
pathways potentially associated with resistance to cancer
immunotherapy primarily anti-PD-1/anti-PD-L1 therapy (44).
In contrast to tumor-infiltrating APCs, pathways related to
the positive regulation of immune and defense response,
including IL-8/IL-6/IL-3/CXCR4 signaling, TREM1 signaling
and leukocyte extravasation pathways were downregulated in
I-MDSCs. Several cytokines signaling pathways, such as IL-8, IL-
6, and IL-3 have been implicated in the positive regulation of
immune response and the activation of T cell responses. IL-8
(45) and IL-6 (46) signaling pathways have a double-sword
function in anti-tumor immunity. IL-8 signaling is known to
recruit leukocytes to the TME via a chemoattractant gradient;
these leukocytes play a role in innate immunity and could
promote anti-tumor immune responses (45). It has beenA
B
C
FIGURE 5 | qRT-PCR validation of selected genes in tumor-infiltrating APCs, PMN-MDSCs and I-MDSCs from CRC tumor tissue. mRNA expression levels for
selected genes in sorted tumor-infiltrating myeloid cells were validated by RT-PCR; PMN-MDSC vs. APC (A); I-MDSC vs. APC (B) and PMN-MDSC vs. I-MDSC (C).
The relative gene expression was normalized to b-actin. Results obtained from two technical replicates of six CRC patients. The P values are indicated as follows;
***P < 0.001, **P < 0.01, *P < 0.05. Data are presented as the mean (Log10) ± standard error of the mean (SEM).November 2020 | Volume 10 | Article 604906
Saleh et al. Tumor-Infiltrating MDSCs in CRCdemonstrated that IL-6 production by TLR-activated APCs drives
the activation of CD4+ T cells and B cell antibody response,
suggesting a role for IL-6 signaling in the activation of immune
responses (47). NFAT-mediated regulation of immune response
and DC maturation pathways were found to be downregulated in
both PMN- and I-MDSCs. NFAT is a key regulator for several key
pathways, including IL-3 production, which is responsible for both
lymphoid and myeloid differentiation (48). We found that IL-3RA
gene was downregulated in both PMN- and I-MDSCs, compared
with APCs (Figures 2A, B). Together, these data suggest the
potential relationship between NFAT and IL-3 pathways, and
may indicate that downregulation of NFAT-IL-3 pathways
interfere with the maturation of myeloid cells in the CRC TME.
We also compared the transcriptional profiles of CRC tumor-
infiltrating PMN-MDSCs with I-MDSCs. RNA-Seq data,
canonical pathway and IPA analyses showed that genes and
pathways related to the crosstalk between DCs and NK cells
were downregulated in PMN-MDSCs, while metabolic pathways
related to oxidative phosphorylation, ketogenesis, glycolysis,Frontiers in Oncology | www.frontiersin.org 9glucogenesis, cholesterol biosynthesis and NRF2-mediated
oxidative stress response were all upregulated in PMN-MDSC.
These pathways could lead to the increased consumption of
glucose, cholesterol metabolism, reduced mitochondrial
respiration, and increased generation of reactive oxygen species,
which all promote tumor growth and survival (49). PMN-MDSCs
could be responsible for enhancing the immunosuppressive
environment within the tumor by mediating glycolysis and
oxidative phosphorylation, leading to lipid accumulation (50). In
turn, lipid uptake by tumor-infiltrating MDSCs enhances their
immunosuppressive activities, which they exert on T cells, thereby
promoting tumorigenesis (50). These results may reflect the
phenotypical, molecular and functional characteristics of each
MDSC subset in the CRC TME.
Based on TCGA analysis for the downregulated genes from
our RNA-Seq data, high gene signature comprising of TREM2,
CATSPER1, NPL, and PRAM1 in tumor-infiltrating PMN-
MDSC predicted poor OS rates in COAD patients. Triggering
receptor expressed on myeloid cells 2 (TREM2) gene isA
B D
C
FIGURE 6 | Kaplan-Meier curves for overall survival and disease-free survival according to the identified gene signatures in tumor-infiltrating PMN-MDSCs and I-
MDSCs. Patients were divided into high and low groups based on median gene expression. Kaplan-Meier curves illustrate the duration of overall survival (OS) (A, C)
and disease-free survival (DFS) of 270 patients (B, D) according to the expression of identified gene signatures in cohorts of patients in the Cancer Genome Atlas
(TCGA) colorectal adenocarcinoma dataset. The Log-rank test was used for curve comparison. The survival signature score is calculated by mean value of log2
(TPM7nbsp;+ 1) of each gene.November 2020 | Volume 10 | Article 604906
Saleh et al. Tumor-Infiltrating MDSCs in CRCimportant for the activation of macrophages and DCs, and
secretion of inflammatory cytokines, while PML-RARA
Regulated Adaptor Molecule 1 (PRAM1) gene could be
associated with neutrophil function, myeloid differentiation
and T cell activation (51–54). Therefore, their downregulation
in PMN-MDSC could negatively influence anti-tumor immune
responses and favor disease progression. However, the function
of CATSPER1 and NPL in myeloid cell biology and function
remains unclear. Additionally, high gene signature, with only
thromboxane A synthase 1 (TBXAS1), in PMN-MDSC was
found to be the best predictor for short DFS in patients. The
role of TBXAS1 has been implicated in DC maturation and Th
response, inflammatory response in myeloid cells and lipid
metabolism (50, 55). Hence, low levels of TBXAS1 could favor
tumor escape from anti-tumor immunity and may also support
PMN-MDSC suppressive functions. In tumor-infiltrating I-
MDSC, high gene signature comprising of TNNT1, NPL and
CATSPER1 predicted poor OS rates in COAD patients.
Moreover, high signature of TNNT1, IL3RA and INHBA in I-
MDSC predicted short DFS in COAD patients. Downregulation
of IL-3 signaling pathway is associated with impairment of DC
maturation and activation of adaptive immune response (56),
and hence could be associated with diminished ability of tumor
eradication, and poor survival rates. Like NPL and CATSPER1,
the roles of TNNT1, and INHBA (gene encodes a member of
TGF-b family and act as a growth/differentiation factor) in
myeloid cell biology and function are not clear.
Together, our findings highlight different molecular and
functional pathways regulated by PMN-MDSCs and I-MDSCs
in CRC TME, compared to APCs, and provide novel insights
into gene signatures for each subset, which could predict poor OS
and DFS in CRC patients. Some of these genes/pathways could
be targeted in MDSCs and could have a clinical benefit in CRC
patients. Notably, this study included six CRC patients and there
were no functional assays used to validate the findings presented
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